Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Production of Pharmaceuticals

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Recombinant DNA

Recombinant DNA

Immunoprecipitation

Immunoprecipitation

Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Plain language summary: a phase 2/3 study of plasminogen, human-tvmh for the treatment of children and adults with type 1 plasminogen deficiency.

Expert review of hematology·2026

Same author

Do Birthweight-For-Gestational Age Centiles Predict Serious Neonatal Morbidity and Neonatal Mortality?

Paediatric and perinatal epidemiology·2025

Same author

Safety and Efficacy of Long-Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Same author

Case Report: Respiratory lesions successfully treated with intravenous plasminogen, human-tvmh, replacement therapy in four patients with plasminogen deficiency type 1.

Frontiers in pediatrics·2024

Same author

Prevalence and incidence of pelvic organ prolapse, bowel and urinary dysfunction in the Integrated Woman's Health Program.

Maturitas·2024

Same author

Associations between hypertension with reproductive and menopausal factors: An integrated women's health programme (IWHP) study.

PloS one·2024

Search research articles

Related Experiment Video

Updated: May 13, 2026

Development of Recombinant Proteins to Treat Chronic Pain

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

Recombinant protein based therapeutics for IPF.

Joseph M Parker¹, Michael S Kramer, Lynne A Murray

¹MedImmune, One MedImmune Way, Gaithersburg, MD, USA.

Inflammation & Allergy Drug Targets

|March 23, 2013

Summary

This summary is machine-generated.

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with no effective treatments. This review explores recombinant protein therapies and the bleomycin mouse model for understanding IPF pathophysiology and developing new treatments.

More Related Videos

Recombinant Collagen I Peptide Microcarriers for Cell Expansion and Their Potential Use As Cell Delivery System in a Bioreactor Model

Recombinant Collagen I Peptide Microcarriers for Cell Expansion and Their Potential Use As Cell Delivery System in a Bioreactor Model

Published on: February 7, 2018

Related Experiment Videos

Last Updated: May 13, 2026

Development of Recombinant Proteins to Treat Chronic Pain

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

Recombinant Collagen I Peptide Microcarriers for Cell Expansion and Their Potential Use As Cell Delivery System in a Bioreactor Model

Recombinant Collagen I Peptide Microcarriers for Cell Expansion and Their Potential Use As Cell Delivery System in a Bioreactor Model

Published on: February 7, 2018

Area of Science:

Pulmonology
Fibrotic Diseases
Drug Discovery

Background:

Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and fatal interstitial lung disease of unknown origin.
Risk factors include smoking, environmental exposures, and genetic predisposition, with familial cases in 5% of patients.
A significant unmet medical need exists due to the lack of effective anti-fibrotic therapies for IPF.

Purpose of the Study:

To review recombinant protein-based therapeutic approaches for IPF.
To examine the pathophysiology of lung fibrosis using the bleomycin-induced mouse model.

Main Methods:

Literature review of recombinant protein therapies for IPF.
Analysis of the bleomycin mouse model for studying lung fibrosis.

Main Results:

Recombinant protein-based therapies represent a promising avenue for IPF treatment.
The bleomycin mouse model effectively recapitulates key aspects of IPF pathophysiology.

Conclusions:

Recombinant protein strategies offer potential for novel IPF treatments.
Further research utilizing models like the bleomycin mouse model is crucial for advancing IPF therapy.